131 related articles for article (PubMed ID: 22292395)
1. [Research about re-evaluation of screening of traditonal Chinese medicine symptoms item of post-marketing medicine Xuezhikang].
He W; Xie Y; Wang Y
Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2898-900. PubMed ID: 22292395
[TBL] [Abstract][Full Text] [Related]
2. [Study on method on post-marketing traditonal Chinese medicine safety assessment].
Kou Q; Zhao S; Feng G; Xie Y
Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2771-5. PubMed ID: 22292361
[TBL] [Abstract][Full Text] [Related]
3. [Basic requirements on post-marketing clinical re-evaluation of chinese medicine and phase IV clinical trials].
Xie Y; Wang Y; Tian F; Wang Y
Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2764-7. PubMed ID: 22292359
[TBL] [Abstract][Full Text] [Related]
4. [Discussion on development of four diagnostic information scale for clinical re-evaluation of postmarketing herbs].
He W; Xie Y; Wang Y
Zhongguo Zhong Yao Za Zhi; 2011 Dec; 36(24):3548-50. PubMed ID: 22368876
[TBL] [Abstract][Full Text] [Related]
5. [Construction and realization of real world integrated data warehouse from HIS on re-evaluation of post-maketing traditional Chinese medicine].
Zhuang Y; Xie B; Weng S; Xie Y
Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2883-7. PubMed ID: 22292392
[TBL] [Abstract][Full Text] [Related]
6. [Sample size calculation in clinical post-marketing evaluation of traditional Chinese medicine].
Fu Y; Xie Y
Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2904-6. PubMed ID: 22292397
[TBL] [Abstract][Full Text] [Related]
7. [Explore method about post-marketing safety re-evaluation of Chinese patent medicines based on HIS database in real world].
Yang W; Xie Y; Zhuang Y
Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2779-82. PubMed ID: 22292363
[TBL] [Abstract][Full Text] [Related]
8. [Post-marketing re-evaluation about usage and dosage of Chinese medicine based on human population pharmacokinetics].
Jiang J; Xie Y
Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2811-2. PubMed ID: 22292372
[TBL] [Abstract][Full Text] [Related]
9. [Guidance of FDA risk evaluation and mitigation strategy and enlightenment to drug risk management of post-marketing Chinese medicine].
Li Y; Xie Y
Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2825-7. PubMed ID: 22292376
[TBL] [Abstract][Full Text] [Related]
10. [Designs and thoughts of real world integrated data warehouse from HIS on re-evaluation of post-maketing traditional Chinese medicine].
Zhuang Y; Xie B; Weng S; Xie Y
Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2880-2. PubMed ID: 22292391
[TBL] [Abstract][Full Text] [Related]
11. [Phase 0 clinical trials and post-marketed re-evaluation of clinical safety in injection of traditional Chinese medicine].
Wei X; Zhang Z; Xie Y; Wang Y
Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2874-6. PubMed ID: 22292389
[TBL] [Abstract][Full Text] [Related]
12. [Clinical orientation and thought on several problems in post-marketed reassessment of traditional Chinese medicine].
Wang X; Su X; Yu J; Xie Y; Wang Y
Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2893-7. PubMed ID: 22292394
[TBL] [Abstract][Full Text] [Related]
13. [Design requirements for clinical trials on re-evaluation of safety and efficacy of post-marketed Chinese herbs].
Xie Y; Wei X
Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2768-70. PubMed ID: 22292360
[TBL] [Abstract][Full Text] [Related]
14. [Process and key points of clinical literature evaluation of post-marketing traditional Chinese medicine].
Liu H; Xie Y
Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2848-50. PubMed ID: 22292382
[TBL] [Abstract][Full Text] [Related]
15. [Application of Markov model in post-marketing pharmacoeconomic evaluation of traditional Chinese medicine].
Wang X; Su X; Sun W; Xie Y; Wang Y
Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2844-7. PubMed ID: 22292381
[TBL] [Abstract][Full Text] [Related]
16. [Postmarketing herbs clinical evaluation should concern about re-evaluating symptoms].
He W; Xie Y; Wang Y
Zhongguo Zhong Yao Za Zhi; 2010 Jun; 35(11):1498-500. PubMed ID: 20822030
[TBL] [Abstract][Full Text] [Related]
17. [Thought on several problems of post-marketing herbs clinical evaluation in special populations].
Zhou A; Lian F
Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2776-8. PubMed ID: 22292362
[TBL] [Abstract][Full Text] [Related]
18. [Application of nested case-control study on safe evaluation of post-marketing traditional Chinese medicine injection].
Xiao Y; Zhao Y; Xie Y
Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2796-8. PubMed ID: 22292368
[TBL] [Abstract][Full Text] [Related]
19. [Technical specification for re-evaluation of post-marketing clinical effectiveness of traditional Chinese medicine (first draft)].
Zhao Y; Yang YY; Wang YX; Yang HM; Wu SX
Zhongguo Zhong Yao Za Zhi; 2018 Aug; 43(15):3211-3215. PubMed ID: 30200720
[TBL] [Abstract][Full Text] [Related]
20. [Clinical orientation of post-marketing Chinese patent drugs: an evidence-based practice].
Shang HC; Zhang BL; Li YP
Zhong Xi Yi Jie He Xue Bao; 2008 Sep; 6(9):887-90. PubMed ID: 18782528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
